



Eli Lilly and Co / LLY

Equity | Generated Sep 9, 2026 11:31 PM EDT

Current price	Daily move	Bid / Ask	Previous close
\$1,126.70	+2.79 +0.25%	\$1,124.21/\$1,128.20	\$1,123.91

Market	NYSE
Industry	Pharmaceuticals
Market data as of	Sep 9, 2026 11:31 PM EDT

JW Intelligence Report

Complete | 3 of 3 sections | Sep 9, 2026 6:50 PM EDT

JW Rank	Rank label	Confidence	IV percentile
56.1 / 100	Balanced	high	26 / 100
Model reference	Upside scenario	Risk reference	Wheel strategy fit
\$1,115.00	\$1,180.00	\$1,090.00	57 / 100

Options stance	bullish
Tail-risk safety	32 / 100
JW Rank data coverage / as of	100.0% Sep 9, 2026 6:50 PM EDT

Key insight

LLY Shows Bullish Sentiment Despite Recent Pullback

Market read

The market appears bullish on LLY despite a recent pullback. The stock is trading near its 200-day moving average, suggesting potential support. Positive news flow includes strong Q2 earnings, FDA approval for Mounjaro, and an acquisition of Merida Biosciences. While short-term bearish notes exist due to sector weakness and technical breakdown, analysts remain optimistic with price targets above the current level.

Strategy context

The option market shows a bullish skew with higher call open interest than put open interest. The term structure is backwardated, suggesting expectations for lower volatility in the future.



JW AI conclusions

Short- and medium-term model interpretation

AI context bias

Bullish

AI analysis updated

Sep 9, 2026 2:04 PM EDT

Short-term scenario

Cautious dip-buy for potential oversold bounce over 1-3 weeks; high uncertainty from sector/macro weakness, rates, and technical breakdown. Prefer confirmation of support hold.

Three-month outlook

Moderately bullish with ~15-20% upside potential toward consensus analyst targets of \$1290-1340, supported by continued GLP-1 volume, raised guidance, pipeline (retatrutide submissions 2027), and manufacturing expansion. High uncertainty remains due to premium valuation (PEG ~1.3), competition, reimbursement/access risks, interest-rate sensitivity, and broader market/healthcare volatility; possible range 1050-1250 with upside bias if sentiment stabilizes.

Market sentiment

Mixed/cautiously constructive. Analysts reiterating Outperform with \$1400 PT citing Foundayo access and incretin growth. Positive mentions of compounding crackdown boosting branded demand. Some short-term bearish notes on recent red days, watchlists targeting 1200 resistance, and market/liquidity pressure. Overall, long-term obesity franchise strength acknowledged but near-term volatility and valuation concerns dominate.

Supporting evidence

LLY's stock price is trading near its 200-day moving average, indicating potential support. | Recent positive news includes strong Q2 earnings, FDA approval for Mounjaro, and an acquisition of Merida Biosciences. | Analysts are reiterating Outperform ratings with price targets above the current level.


Risk watch

Sector weakness and technical breakdown could lead to further short-term downside. | Valuation concerns remain due to LLY's premium P/E ratio.



Enhanced price structure

45 trading days with volume, model levels and current technical reference bands




45 complete trading-session observations



JW Rank factors

Score, source coverage and interpretation for each decision factor



Decision summary

Primary model reads before the detailed indicator appendix

Momentum

bullish_recovery

Institutional flow

Below MVWAP

Structure

Above 200D trend

Volatility

medium



Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	BULLISH RECOVERY neutral MACD decelerating
Trend signal	BULLISH RECOVERY
RSI signal	neutral
RSI (7 / 14 / 21)	22.25 / 37.00 / 42.67
RSI velocity	-2.09
MACD line / signal / histogram	-14.28 / - / -3.45
MACD acceleration	-3.00
Stochastic K / D	6.61 / 8.71

Institutional footprints

Volume-weighted cost, price location and flow

Current read	Below institutional MVWAP Distribution bias
Institutional flow	-3.04
20-day MVWAP	\$1,199.46
Price vs 20-day MVWAP	-6.07%
Daily reference VWAP	\$1,127.33
Price vs daily reference	-0.06%
Volume	942.71K

Structural context

Long-term trend and volatility boundaries

Current read	Above 200-day trend Negative macro velocity
Macro velocity	-3.92
20-day / 200-day SMA	\$1,192.65 / \$1,064.17
Bollinger range	\$1,103.56 - \$1,281.75
Bollinger position	0.116



Options and volatility intelligence


Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
26 / 100	28 / 100	93.26	148.86

Market regime	DANGER ZONE
Tail-risk regime	NORMAL TAIL RISK
Term structure	backwardation
Term slope	-3.77 pts
Skew read	balanced
Liquidity / quote coverage	100.0%
Options Snapshot IV sources	ATM: option chain Rank/percentile: fundamentals
Options Snapshot IV observed at	Sep 9, 2026 2:51 PM EDT
Options data quality	Coverage 88.9%

Option term structure

ATM implied-volatility curve by days to expiration



EXPIRATION	DTE	ATM IV	STATE
2026-09-11	2	36.6%	-
2026-09-18	9	32.7%	-
2026-09-25	16	32.8%	-




Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bull Put Spread reference


Short \$1,100.00 | Long \$1,095.00 | Width \$5.00 | Net credit \$0.82



Max profit \$82.00 | Max loss -\$418.00 | Break-even \$1,099.18 | Per contract at expiry

Bear Call Spread reference

Short \$1,145.00 | Long \$1,150.00 | Width \$5.00 | Net credit \$1.17



Max profit \$117.00 | Max loss -\$383.00 | Break-even \$1,146.17 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	2026-10-29
Earnings IV-crush risk	NOT MEASURED
VIX	16.19
VVIX	93.26
SKEW index	148.86
Observation confidence	high
Option quote quality	reliable
Contracts observed	100



Event and tail-risk context (continued)

Known event windows and broad volatility conditions

FIELD	VALUE
Contracts with quotes	100

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The market appears bullish on LLY despite a recent pullback. The stock is trading near its 200-day moving average, suggesting potential support. Positive news flow includes strong Q2 earnings, FDA approval for Mounjaro, and an acquisition of Merida Biosciences. While short-term bearish notes exist due to sector weakness and technical breakdown, analysts remain optimistic with price targets above the current level.

Options context

LLY Shows Bullish Sentiment Despite Recent Pullback

Wheel context

The option market shows a bullish skew with higher call open interest than put open interest. The term structure is backwardated, suggesting expectations for lower volatility in the future.

Observed evidence

LLY's stock price is trading near its 200-day moving average, indicating potential support. | Recent positive news includes strong Q2 earnings, FDA approval for Mounjaro, and an acquisition of Merida Biosciences. | Analysts are reiterating Outperform ratings with price targets above the current level.

Principal risks to monitor

Sector weakness and technical breakdown could lead to further short-term downside. | Valuation concerns remain due to LLY's premium P/E ratio.



Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization	P/E (TTM)
\$1.06T	40.51
ROE	Revenue growth
92.6%	31.7%
EPS growth	Operating margin
49.3%	42.2%
Net profit margin	Gross margin
33.5%	-
Free cash flow CAGR	Debt / equity
5.9%	1.60
Dividend yield	Beta
0.8%	0.43
52-week range	
\$712.05 - \$1,292.65	

Company or fund profile

Issuer identity and classification

Name	Market
Eli Lilly and Co	NYSE
Industry	Country
Pharmaceuticals	US
Currency	IPO date
USD	1970-07-09
Shares outstanding	52-week return
941.74M	58.1%
Book value per share	Revenue per share
\$35.98	\$89.14
Website	lilly.com



Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal
Covered Call | 2026-09-18
At signal \$1,126.78 | Current \$1,126.70
SHORT Option \$1,130.00 B \$22.00 / A \$25.10
High turnover | Conservative | CR \$23.55

Sep 9, 2026 12:08 PM EDT



Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	\$34.36
ATR as % of price	3.1%
Volatility environment	medium
Current IV	32.2%
IV rank	24 / 100
IV percentile	26 / 100
Technical Snapshot IV source	Private fundamentals snapshot
Technical Snapshot IV observed at	Sep 9, 2026 7:31 PM EDT

Technical health and risk radar

Derived indicator health and event context

Overall health	70 / 100
Trend health	78 / 100
Momentum health	68 / 100
Volatility health	64 / 100
Structure health	62 / 100
Earnings risk / date	low 2026-10-29
Macro risk	unknown
Volatility risk	medium
Structure risk	medium

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	\$1,192.65 / \$1,187.70 / \$1,064.17
EMA (9 / 21)	\$1,155.18 / \$1,175.29
Bollinger upper / middle / lower	\$1,281.75 / \$1,192.65 / \$1,103.56



Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	0.116
True high / low	\$1,138.79 / \$1,119.00
5-day true high / low	\$1,187.83 / \$1,113.55

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	-3.920	-
SMA50	-1.122	-
MVWAP20	-3.038	-
MACD	-3.000	-
RSI	-2.091	-
Volume	-2305.670	-
ATR	-0.728	-
T1	-	-11.46 / 1203.24 / 1149.36 / 1113.55
T2	-	-7.66 / 1207.47 / 1159.60 / 1138.30
T3	-	-5.28 / 1208.57 / 1171.66 / 1137.50



Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	\$1,121.39
Options Snapshot IV sources	ATM: option chain Rank/percentile: fundamentals
Options Snapshot IV observed at	Sep 9, 2026 2:51 PM EDT
Options data coverage	88.9%
SKEW regime	HIGH TAIL RISK SKEW
VVIX regime	VVIX FLAT
Front expiration / DTE	2026-09-11 2 DTE
Front at-the-money IV	36.6%
25-delta skew	1.15
Put / Call 25-delta	\$1,100.00 Delta -0.239 / \$1,145.00 Delta 0.231
Median option bid/ask spread	18.8%
Bid/ask spread	-
Contracts observed / quoted	100 / 100

Price context

Last Price: 1,121.39 | Bid: 1,121.29 | Ask: 1,121.49 | Previous Close: 1,123.91 | Change: -2.52 |
Daily change: -0.22% | Update Time: 2026-09-09T14:51:27.761470-04:00 | Latest History Date: 2026-09-09
| Latest History Price: 1,121.49

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-15 | Latest Date: 2026-09-09 | Latest Price:
1,121.49 | Max Drawdown 60d Percent: -12.41%

Fundamental context

Current Iv Percent: 32.47% | Iv Rank: 25.54 | Iv Percentile: 28.29 | Next Earnings Date: 2026-10-29 |
Ex Dividend Date: 2026-08-13



Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Generated Sep 9, 2026 11:31 PM EDT. Jason Wheel Terms of Use and Privacy Policy apply. Copyright Jason Wheel Research LLC. All rights reserved.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	jasonwheel.com
Terms of Use	jasonwheel.com / Terms
Privacy Policy	jasonwheel.com / Privacy
Options Disclosure Document	theocc.com / Options Disclosure Document